CoChat

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

Open access
Herter, Sylvia, Morra, Laura, Schlenker, Ramona, Sulcova, Jitka, Fahrni, Linda, Waldhauer, Inja, Lehmann, Steffi, Reisländer, Timo, Agarkova, Irina, Kelm, Jens M., Klein, Christian, Umana, Pablo, Bacac, Marina · 2017 · Cancer Immunology, Immunotherapy
Cited by 138

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The complexity of the tumor microenvironment is difficult to mimic in vitro, particularly regarding tumor-host interactions. To enable better assessment of cancer immunotherapy agents in vitro, we developed a three-dimensional (3D) heterotypic spheroid model composed of tumor cells, fibroblasts, and immune cells. Drug targeting, efficient stimulation of immune cell infiltration, and specific elimination of tumor or fibroblast spheroid areas were demonstrated following treatment with a novel immunocytokine (interleukin-2 variant; IgG-IL2v) and tumor- or fibroblast-targeted T cell bispecific antibody (TCB). Following treatment with IgG-IL2v, activation of T cells, NK cells, and NKT cells was demonstrated by increased expression of the activation marker CD69 and enhanced cytokine secretion. The combination of TCBs with IgG-IL2v molecules was more effective than monotherapy, as shown by enhanced effects on immune cell infiltration; activation; increased cytokine secretion; and faster, more efficient elimination of targeted cells. This study demonstrates that the 3D heterotypic spheroid model provides a novel and versatile tool for in vitro evaluation of cancer immunotherapy agents and allows for assessment of additional aspects of the activity of cancer immunotherapy agents, including analysis of immune cell infiltration and drug targeting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-016-1927-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 138

Metadata

Authors
Herter, S., Morra, L., Schlenker, R., Sulcova, J., Fahrni, L., Waldhauer, I., Lehmann, S., Reisländer, T., Agarkova, I., Kelm, J. M., Klein, C., Umana, P., & Bacac, M.
Venue
Cancer Immunology, Immunotherapy
Published
2016-11-17
Volume
66
Issue
1
Pages
129-140
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2550597146
Cited by
138
References
5
FWCI
4.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. https://app.cochat.ai/papers/10.1007/s00262-016-1927-1
The paper
Herter, S., Morra, L., Schlenker, R., Sulcova, J., Fahrni, L., Waldhauer, I., Lehmann, S., Reisländer, T., Agarkova, I., Kelm, J. M., Klein, C., Umana, P., & Bacac, M. (2017). A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-016-1927-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.